Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors-Reference-Cited by-同舟云学术

Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors

Published:2021-01-01 Issue:1 Volume:24 Page:806-815
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Burne Rebecca¹,Balu Sanjeev²,Guérin Annie¹,Bungay Rebecca¹,Sin Roxana²,Paul Mary Lisha²

Affiliation:

1. Analysis Group, Montréal, Canada

2. Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1939705

Reference52 articles.

1. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States

2. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

3. Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer

4. Breast cancer as a systemic disease: a view of metastasis

5. Treatment of metastatic breast cancer: second line and beyond

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy;Expert Review of Pharmacoeconomics & Outcomes Research;2023-07-17

2. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers;Cancer Research;2023-06-29

3. CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan;Cell Cycle;2023-06-02

4. Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS);Clinical and Translational Oncology;2023-04-07

5. Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands;JAMA Network Open;2023-02-16